Pegasys 180 micrograms solution for injection in pre-filled syringe
Sponsors
Centre Hospitalier Universitaire De Nice, Karolinska University Hospital, Vir Biotechnology Inc., Kartos Therapeutics Inc.
Conditions
Chronic Hepatitis B Virus (HBV) InfectionChronic Hepatitis B Virus InfectionExtramembranous glomerulonephritisPrimary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) With Intermediate Or High-Risk TP53 Wild-Type (TP53 WT) Who Are Relapsed Or Refractory to Janus Kinase (JAK) - Inhibitor Treatmenthepatitis D
Phase 2
Study of immunological activity after personalized immunomodulatory therapy regulating the Th17 pathway in patients with extramembranous glomerulonephritis
CompletedCTIS2023-503226-39-00
Start: 2023-07-18End: 2025-09-14Target: 5Updated: 2024-07-22
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection
Active, not recruitingCTIS2024-513177-48-00
Start: 2022-06-16Target: 24Updated: 2025-12-02
A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL)
CompletedCTIS2024-513176-17-00
Start: 2023-03-30End: 2025-08-19Target: 13Updated: 2025-09-03
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
Active, not recruitingCTIS2024-513912-89-00
Start: 2018-12-13Target: 253Updated: 2025-09-17